Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics announced four upcoming presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations and two oral presentations. These presentations will detail new data from clinical trials of aficamten, a cardiac myosin inhibitor, for both obstructive and non-obstructive hypertrophic cardiomyopathy. The company also provided an update on its pipeline of other potential new medicines for cardiac muscle dysfunction.
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy
Cytokinetics will present four research papers, including two Late Breaking Clinical Research presentations, on aficamten for non-obstructive hypertrophic cardiomyopathy at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. These presentations, scheduled for October 12, 2026, will cover aficamten's global efficacy, its impact on exercise performance, and its association with right ventricular function, as well as dosing and safety. The company plans to submit a Supplemental New Drug Application for aficamten in Q4 2026, based on recent positive clinical trial results.
CYTK4910847 Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for CYTK4910847, a 4.0% bond issued by Cytokinetics, Inc. maturing on November 15, 2026. It outlines key facts about the issuer and the bond, including its issue date, maturity date, face value, and minimum denomination. The profile also details the semi-annual coupon payment schedule, past and upcoming payouts, and the bond's outstanding amount.
Cytokinetics launches ASPEN-HCM and analysts rate Cytokinetics stock a Buy
Cytokinetics launched ASPEN-HCM, a real-world study for its drug MYQORZO in obstructive hypertrophic cardiomyopathy, aiming to enroll 400 patients to track safety and effectiveness. This comes as the company reported Q2 2026 revenue of $28.62 million, significantly above consensus, despite a net loss due to heavy investment in its cardiovascular pipeline. Analysts maintain a "Buy" rating on the stock, with a consensus target price of $103.37, reflecting optimism about MYQORZO's commercial potential and the ongoing pipeline development.
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Cytokinetics (CYTK) has seen its fair value estimate increase to $107.80, driven by positive views on its Myqorzo launch and potential contributions from non-obstructive hypertrophic cardiomyopathy indications. Analysts project significant revenue growth and a pathway to profitability, contingent on successful commercial execution and regulatory milestones. The company faces risks including regulatory setbacks, high expenses, and competition, but is supported by strong clinical data and strategic capital management.
A new study aims to enroll about 400 adults to assess a heart drug in everyday care.
Cytokinetics has initiated the ASPEN-HCM study, a real-world observational trial evaluating its drug MYQORZO (aficamten) in approximately 400 adult patients with symptomatic obstructive hypertrophic cardiomyopathy. The multicenter study, led by the University of California, San Francisco, will assess the drug's safety, effectiveness, and economic impact in routine clinical practice over 12 to 36 months. Outcomes will include changes in heart function, treatment patterns, and patient-reported measures, as well as the drug's potential to avoid or delay invasive therapies.
Cytokinetics launches real-world study of heart drug MYQORZO
Cytokinetics has initiated ASPEN-HCM, a real-world observational study to assess the safety and effectiveness of its heart drug MYQORZO (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The study, led by the University of California, San Francisco, aims to enroll approximately 400 patients across 13 cardiology practices. MYQORZO, an approved oral cardiac myosin inhibitor, will be evaluated for its impact on cardiac function, treatment discontinuations, and healthcare resource utilization.
Cytokinetics (CYTK) Launches ASPEN-HCM Study to Evaluate Myqorzo in Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Inc (CYTK) has launched the ASPEN-HCM study to assess the real-world effectiveness of Myqorzo in adults with symptomatic obstructive hypertrophic cardiomyopathy. Despite a high Price-to-Sales ratio of 122.69 and ongoing unprofitability, the market anticipates future growth from Myqorzo and other pipeline assets. The company's GF Score is 57/100, indicating strong momentum but weak financial strength and profitability, while insider activity shows significant selling.
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has launched ASPEN-HCM, a real-world study to evaluate its drug MYQORZO® (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This multicenter, observational study aims to track the safety, clinical effectiveness, and healthcare resource impact of MYQORZO in routine clinical practice, building upon previous clinical trial data. The study, led by the University of California, San Francisco (UCSF), will enroll approximately 400 patients over 12 to 36 months to assess various clinical and economic outcomes, including reductions in left ventricular ejection fraction and changes in patient-reported outcomes.
Cytokinetics Announces Start of ASPEN-HCM Real-World Study of MYQORZO in Symptomatic Obstructive HCM
Cytokinetics has launched the ASPEN-HCM real-world study to assess the safety, effectiveness, and healthcare resource impact of MYQORZO (aficamten) in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This observational study will enroll approximately 400 patients across 13 cardiology centers, building on previous clinical trials and aiming to provide insights for clinical decision-making. Despite its potential, MYQORZO carries a Boxed WARNING due to the risk of heart failure from systolic dysfunction, necessitating extensive monitoring and restricting its use under a REMS program.
Equity in earnings of Cytokinetics, Incorporated – HAN:KK3A
This article provides financial information for Cytokinetics, Incorporated (HAN:KK3A) on the Hannover Stock Exchange, specifically focusing on its equity in earnings. It appears to be a stub or data-oriented entry from TradingView, offering an overview of the company's financial data. The content includes placeholders for period values and changes, indicating it is likely a financial data display.
Cytokinetics insiders, including CEO, sell significant shares amid stock trading below moving averages.
Cytokinetics CEO Robert I. Blum and other executives have recently sold a substantial amount of company stock, with Blum alone selling nearly 105,000 shares. This significant insider selling activity is occurring while the company's stock is trading below both its 50-day and 200-day moving averages, despite the 50-day average being higher. The company remains unprofitable with a negative P/E ratio, suggesting potential challenges ahead and that the insider sales may signal cautious sentiment regarding Cytokinetics' near-term prospects.
Cytokinetics CEO Robert Blum sells $490,949 in stock By Investing.com
Cytokinetics CEO Robert Blum sold 7,500 shares of company common stock worth $490,949 after exercising non-qualified stock options. Following the transactions, Blum directly holds 278,544 shares and 149,245 derivative securities. This comes amidst positive analyst revisions for earnings and strong sales for the company's drug Myqorzo.
Form 4 Cytokinetics Inc For: 29 September By Investing.com
This article announces the filing of a Form 4 for Cytokinetics Inc. on September 29, 2026. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders (officers, directors, or beneficial owners of more than 10% of a company's stock) whenever they trade shares of their own company's stock. The article itself provides minimal detail beyond the announcement, serving as a notification rather than an in-depth report on the transaction.
Cytokinetics CEO Robert Blum sells $490,949 in stock
Robert Blum, CEO and Director of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of company common stock for $490,949 after exercising non-qualified stock options. Following the transactions, Blum directly holds 278,544 shares and 149,245 derivative securities. This insider sale comes amidst other company news, including strong second-quarter sales for Myqorzo, a raised price target from Barclays, and ongoing litigation regarding patent infringement.
At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options.
Cytokinetics President & CEO Robert I. Blum exercised 7,500 non-qualified stock options at $10.60 per share and immediately sold the acquired common shares at $65.46 per share, generating an approximate pre-tax spread of $411K. These transactions, executed on September 28, 2026, were conducted under a Rule 10b5-1 plan. Following these trades, Blum retained 149,245 non-qualified stock options, along with direct and indirect common stock holdings.
Cytokinetics stock gains 2.15 percent as analysts target USD 109.90
Cytokinetics stock rose by 2.15% to USD 66.05 following strong second-quarter revenue of USD 28.6 million, largely driven by Myqorzo sales reaching USD 25.3 million. Despite operating at a net loss, analysts remain optimistic, with an average 12-month price target of USD 109.90, signaling significant potential upside. The company is also planning a supplemental New Drug Application for aficamten in non-obstructive hypertrophic cardiomyopathy in Q4 2026.
Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates
Cytokinetics (CYTK) is seeing accelerating uptake for MYQORZO in the US and Germany for obstructive HCM, with patient starts increasing. The company is also advancing its heart failure pipeline through the COMET (omecamtiv mecarbil) and AMBER (ulacamten) programs, supported by strategic partnerships. Cytokinetics has outlined a Vision 2030 plan to expand its therapies, indications, and patient reach globally.
CYTK5615147 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Cytokinetics, Incorporated (CYTK5615147) bond, highlighting its key facts such as issue and maturity dates, face value, and issuer information. It also outlines the bond's interest payment schedule with a fixed semi-annual coupon rate of 3.50% and details upcoming and past coupon payouts. Additionally, the profile includes redemption information, showing an outstanding amount of $140.53 million USD.
Cytokinetics (CYTK) Pullback Puts Its Heart Drug Valuation Story Back In Focus
Cytokinetics (CYTK) has experienced a recent stock pullback, with its share price dropping significantly over the past month and three months, though still showing solid longer-term gains. Despite the short-term dip, the company is considered 40% undervalued based on a fair value estimate of $107.80, with its heart disease franchise and late-stage pipeline driving the valuation debate. The article encourages investors to analyze the company's risks and rewards, suggesting further research using focused screeners for quality, value, and resilience.
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics executives presented their commercial expansion plans, cardiovascular pipeline, and business development priorities at a Bernstein investor symposium. The company highlighted the successful launch of MYQORZO for obstructive hypertrophic cardiomyopathy (HCM) and discussed clinical programs targeting various forms of heart failure. Cytokinetics aims to become a leading specialty cardiology company by 2030, with goals including two approved therapies across three indications and reaching over 100,000 patients.
Cytokinetics at bernstein healthcare forum: push beyond first launch
Cytokinetics outlined its "Vision 2030" plan at the Bernstein Healthcare Forum, aiming to evolve into a global cardiovascular company with two approved therapies across three indications, 10 new molecular entities, and a presence in over 15 countries. The company highlighted strong early momentum for its first commercial drug, MYQORZO, while also detailing its long-term clinical development plans for omecamtiv mecarbil and ulacamten in heart failure. Cytokinetics emphasizes its commitment to direct commercialization in key Western markets and strategic partnerships elsewhere, driven by its scientific foundation in cardiac myosin inhibition.
Form 4 Cytokinetics Inc For: 22 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Cytokinetics Inc. dated September 22. It provides no further details about the content of the Form 4 but lists the company's stock symbol as CYTK with a -0.23% change. The rest of the content includes navigation, ads, and various market data unrelated to the filing itself.
Cytokinetics EVP Fady Malik sells $239k in company stock
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc. (NASDAQ:CYTK), sold 3,500 shares of company common stock for $239,015 on September 22, 2026. Simultaneously, Malik exercised options to acquire 3,500 shares for $27,300, leading to a direct holding of 153,902 shares. This transaction follows recent positive news for Cytokinetics, including strong Myqorzo sales, an increased price target from Barclays, ongoing patent litigation, and reiterated "Overweight" or "Buy" ratings from analysts like Cantor Fitzgerald, Truist Securities, and H.C. Wainwright.
Form 4 Cytokinetics Inc For: 22 September By Investing.com
This article reports on a Form 4 filing for Cytokinetics Inc. on September 22. It briefly mentions the company's stock performance and was published by Investing.com. The content mainly consists of market data and navigational elements.
Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years
Cytokinetics (NASDAQ: CYTK) has significantly outperformed the market over the last 15 years, achieving an average annual return of 15.99%. An initial investment of $1000 in CYTK stock 15 years ago would now be worth $10,260.61. This highlights the powerful effect of compounded returns on investment growth over time.
Family trust tied to Cytokinetics (NASDAQ: CYTK) CEO just sold about 98,000 shares
Cytokinetics CEO Robert I. Blum and related trusts engaged in several insider transactions. A trust associated with Blum, The Bridget Blum 2026 Irrevocable Trust, sold 97,926 shares of CYTK common stock for $69.33 per share. Blum also exercised stock options for 7,500 shares and sold them under a Rule 10b5-1 plan, disclaiming beneficial ownership in the trust's transactions.
Trust tied to Cytokinetics (NASDAQ: CYTK) CEO moves to sell shares
Cytokinetics CEO Robert I. Blum's trust plans to sell 97,926 shares of Cytokinetics common stock, valued at approximately $7.1 million, according to a Rule 144 SEC filing. The shares were originally acquired as equity compensation between December 2024 and March 2026, with the proposed sale date indicated as September 15, 2026, on NASDAQ. J.P. Morgan Securities LLC is acting as the agent for the sale.
Cytokinetics director Robert Landry sells $72,130 in shares
Cytokinetics director Robert Landry sold 1,000 shares of common stock for $72,130 on September 15, 2026, retaining 8,184 shares. This transaction follows recent positive news for Cytokinetics, including strong Myqorzo sales, analyst target raises, and ongoing patent litigation against Bristol-Myers Squibb and MyoKardia. Several investment firms maintain positive ratings on Cytokinetics due to these developments.
Cytokinetics CEO Blum’s trust sells $6.7m in company shares
Robert I. Blum, CEO of Cytokinetics Inc. (NASDAQ:CYTK), and a trust associated with him, recently sold shares totaling approximately $6.79 million and $550,800, respectively. These transactions, conducted under a Rule 10b5-1 trading plan, involved the trust selling 97,926 shares and Mr. Blum directly selling 7,500 shares after exercising stock options. The company's stock has seen a 39% return over the past year, and analysts remain positive, with several raising price targets following strong Q2 Myqorzo sales and ongoing litigation developments.
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics has announced the call for proposals for its ninth annual Communications Grant Program, aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure. The grants will provide resources for communication, awareness, and community engagement initiatives. Applications are due by October 2, 2026, and recipients will be announced in January 2027.
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics has announced its ninth annual Communications Grant Program, inviting patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure to submit proposals. The program aims to provide financial support for communications, awareness, and community engagement initiatives, recognizing these as often underfunded areas within patient advocacy. The deadline for applications is October 2, 2026, with recipients to be announced in January 2027.
Landry Robert E Disposes of 1,000 CYTOKINETICS INC Shares at $74.66 on September 11, 2026
Landry Robert E, a director at CYTOKINETICS INC, sold 1,000 shares of the company's stock at $74.66 per share on September 11, 2026. This transaction reduced his holdings by approximately 9.8%, leaving him with 9,184 shares. The sale is categorized as an open-market transaction (code S).
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com
Robert E. Landry, a director at Cytokinetics Inc. (NASDAQ:CYTK), sold 1,000 shares of the company's common stock for $74,660. The sale occurred on September 11, 2026, with shares priced at $74.66 each, leaving Landry with 9,184 shares. This transaction took place as Cytokinetics shares have gained 44% over the past year, though InvestingPro analysis suggests the stock is currently overvalued.
Cytokinetics director Robert Landry sells $74,660 in shares
Cytokinetics director Robert Landry sold 1,000 shares of the company's common stock for $74,660 on September 11, 2026. This transaction leaves Mr. Landry with 9,184 directly held shares. The sale follows a strong performance for Cytokinetics shares, which have gained 44% over the past year.
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock
Cantor Fitzgerald has reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK), highlighting positive commercial and regulatory outlooks for the company. Despite not expecting profitability this year, the firm noted strong sales for Myqorzo, continued pipeline development, and potential for expanding aficamten's use. The article also touches on recent analyst price target increases and ongoing patent litigation, reflecting significant activity surrounding Cytokinetics.
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM
Cytokinetics, Incorporated presented at Citigroup's Biopharma Back to School Summit 2026 on September 9, 2026, at 3:00 PM EDT. The event featured Eric Joseph, a senior biotech analyst with Citi, as the presenter. The full transcript of this presentation is reserved for subscribers of MarketScreener.
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential
Truist Securities reiterated a Buy rating and a $112 price target for Cytokinetics (NASDAQ: CYTK) after detailed ACACIA analyses were presented at ESC. The firm sees substantial potential for Cytokinetics' drug, Myqorzo, in hypertrophic cardiomyopathy, projecting $5.8 billion in worldwide peak revenue by 2036. The stock is currently trading at $70.91, up over 100% in the past year, with analyst consensus remaining firmly in Buy territory.
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM
Cytokinetics (CYTK) announced positive Phase 3 results for its drug aficamten (MYQORZO) in treating symptomatic non-obstructive hypertrophic cardiomyopathy, marking the first successful clinical study in this indication. The company plans to submit a supplemental New Drug Application to expand aficamten's label. While this strengthens the case for broader patient use and revenue, existing safety concerns and regulatory requirements for the drug will continue to be scrutinized by investors.
ESC26: Cytokinetics' big data reveal for Myqorzo impresses
Cytokinetics has unveiled promising data from its ACACIA-HCM study for Myqorzo, showing significant clinical improvements in non-obstructive hypertrophic cardiomyopathy (HCM). This positions Myqorzo to potentially double its target market and become the first treatment for this condition, giving it a crucial advantage over its rival, Bristol Myers Squibb's Camzyos, which failed to show similar efficacy in non-obstructive HCM. Analysts predict Myqorzo could achieve peak sales of around $4 billion annually if approved for both forms of HCM.
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
The article details key clinical trial updates from the European Society of Cardiology meeting, focusing on developments in heart disease treatments. Cytokinetics experienced a stock sell-off despite positive Phase 3 results for Myqorzo, due to safety concerns, while Arrowhead Pharmaceuticals showed promising data for plozasiran, potentially positioning it as a best-in-class treatment for severe hypertriglyceridemia. Additionally, the failure of AstraZeneca and Ionis' eplontersen trial sparked debate about the efficacy of RNA interference drugs versus protein stabilizers in treating transthyretin amyloidosis-mediated cardiomyopathy.
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Cytokinetics announced positive primary results from its ACACIA-HCM Phase 3 clinical trial for aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showing significant improvements in quality of life and exercise performance compared to placebo. Based on these results, Cytokinetics plans to submit a supplemental New Drug Application to the FDA in Q4 2026, aiming to make aficamten the first cardiac myosin inhibitor for the full spectrum of symptomatic HCM.
Cytokinetics (CYTK) Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data
Cytokinetics (CYTK) is considered potentially 29% undervalued, with a fair value estimated at $107.80 against its current share price of $76.84, following positive Phase 3 aficamten trial data. The company's ongoing investments in late-stage pipeline assets and its muscle biology platform are expected to drive future growth and reduce reliance on a single product. Investors are encouraged to review the full narrative, including risks like potential regulatory setbacks or high commercialization costs, and to consider other investment opportunities.
Cytokinetics (CYTK) Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data
Cytokinetics (CYTK) is considered potentially 29% undervalued, with a fair value pegged at $107.80 compared to its last close of $76.84, following favorable topline results from its ACACIA-HCM Phase 3 aficamten trial. The company's ongoing investments in late-stage pipeline assets and its muscle biology platform are expected to drive future growth and improve long-term net margins, although risks from regulatory setbacks or high commercialization costs remain.
Cytokinetics CEO Sells 7,500 Shares Amid Strong Stock Performance
Cytokinetics CEO Robert I. Blum sold 7,500 shares for $575,700 on August 10, 2026, after exercising options at a much lower strike price, reflecting gains from the company's strong stock performance. Despite the sale, Blum maintains a significant equity position, demonstrating continued alignment with shareholder interests. Analysts are highly optimistic about Cytokinetics, with 91% rating the stock as a buy and projecting a nearly 40% price increase.
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
Cytokinetics CEO Robert I. Blum sold 7,500 shares of the company's stock for $575,700 after exercising stock options. Despite this sale, Blum retains a significant stake in Cytokinetics, indicating continued alignment with shareholder interests. Analysts maintain a favorable view of Cytokinetics stock, with a median one-year price target suggesting a nearly 40% gain.
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics will present new data on aficamten for hypertrophic cardiomyopathy (HCM) at the European Society of Cardiology (ESC) Congress 2026, including Hot Line and Late-Breaking Science presentations for ACACIA-HCM. The company will also host an investor event to discuss the results. These presentations focus on both obstructive and non-obstructive forms of HCM, highlighting aficamten's potential in treating cardiac muscle dysfunction.
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Cytokinetics (CYTK) has seen a 20.5% year-to-date gain, driven by the FDA approval and strong initial uptake of its drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM). The company is expanding Myqorzo's international presence and developing other pipeline candidates, including omecamtiv mecarbil for heart failure. While Myqorzo's commercial performance is crucial, the stock faces competition and is currently rated a Zacks Rank #3 (Hold) due to its high valuation compared to the industry average.
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics will present new data on its cardiac myosin inhibitor, aficamten, at the European Society of Cardiology (ESC) Congress 2026, including Hot Line and Late-Breaking Science presentations on the ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these results. Additionally, two poster presentations will cover real-world data related to hypertrophic cardiomyopathy.
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026
Cytokinetics will present primary results from its ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress from August 28-31, 2026. The presentations will include a Hot Line session and two Late Breaking Science sessions, with an accompanying investor event on August 28 to discuss these findings. The company is seeking regulatory approval for aficamten in non-obstructive HCM, building on its existing approval for obstructive hypertrophic cardiomyopathy.
